Cancer drug cabozantinib tested in tough prostate cancers

NCT ID NCT04631744

Terminated Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested the drug cabozantinib in men with a hard-to-treat type of prostate cancer that had spread and stopped responding to hormone therapy. The study focused on patients whose tumors had specific genetic changes or had spread to the liver. Only 4 men were enrolled before the trial was stopped early, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib
What this could lead to: If it works, this could point toward a treatment option for men with advanced prostate cancer that has specific genetic changes or spread to the liver.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.